Arvinas, Inc.
ARVNDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How ARVN's past catalysts played out
Breast Cancer
1 drug in this indication
KRAS G12D Mutation
1 drug in this indication
Prostate Cancer Metastatic
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Arvinas, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Arvinas, Inc.'s (ARVN) pipeline across Phase 2. Its lead program is ARV-471 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Arvinas, Inc.'s next FDA catalyst?→
Arvinas, Inc.'s (ARVN) next tracked catalyst is a Phase 2 expected November 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ARVN biotech catalysts?→
Add ARVN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Arvinas, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.